{"id":"NCT01673620","sponsor":"Organon and Co","briefTitle":"A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)","officialTitle":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of Combination Montelukast/Loratadine (MK-0476A) in Mexican Patients With Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07-04","primaryCompletion":"2012-10-10","completion":"2012-10-10","firstPosted":"2012-08-28","resultsPosted":"2014-11-14","lastUpdate":"2024-09-04"},"enrollment":69,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Montelukast 10 mg/loratadine 10 mg","otherNames":["MK-0476A"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Montelukast 10 mg/loratadine 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and tolerability of montelukast 10 mg/loratadine 10 mg versus placebo in Mexican participants with allergic rhinitis.","primaryOutcome":{"measure":"Number of Participants Experiencing at Least One Adverse Event (AE)","timeFrame":"Up to 4 weeks","effectByArm":[{"arm":"Montelukast 10 mg/Loratadine 10 mg","deltaMin":6,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["Dry mouth"]}}